{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:13:14Z","timestamp":1792181594510,"version":"4.4.0"},"reference-count":130,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Invasive fungal diseases (IFDs) still represent a relevant cause of mortality in patients affected by hematological malignancies, especially acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) undergoing remission induction chemotherapy, and in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Mold-active antifungal prophylaxis (MAP) has been established as a standard of care. However, breakthrough IFDs (b-IFDs) have emerged as a significant issue, particularly invasive aspergillosis and non-Aspergillus invasive mold diseases. Here, we perform a narrative review, discussing the major advances of the last decade on prophylaxis, the diagnosis of and the treatment of IFDs in patients with high-risk neutropenic fever undergoing remission induction chemotherapy for AML\/MDS and allo-HSCT. Then, we present our single-center retrospective experience on b-IFDs in 184 AML\/MDS patients undergoing high-dose chemotherapy while receiving posaconazole (n = 153 induction treatments, n = 126 consolidation treatments, n = 60 salvage treatments). Six cases of probable\/proven b-IFDs were recorded in six patients, with an overall incidence rate of 1.7% (6\/339), which is in line with the literature focused on MAP with azoles. The incidence rates (IRs) of b-IFDs (95% confidence interval (95% CI), per 100 person years follow-up (PYFU)) were 5.04 (0.47, 14.45) in induction (n = 2), 3.25 (0.0013, 12.76) in consolidation (n = 1) and 18.38 (3.46, 45.06) in salvage chemotherapy (n = 3). Finally, we highlight the current challenges in the field of b-IFDs; these include the improvement of diagnoses, the expanding treatment landscape of AML with molecular targeted drugs (and related drug\u2013drug interactions with azoles), evolving transplantation techniques (and their related impacts on IFDs\u2019 risk stratification), and new antifungals and their features (rezafungin and olorofim).<\/jats:p>","DOI":"10.3390\/microorganisms12010117","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T03:49:04Z","timestamp":1704685744000},"page":"117","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-2220","authenticated-orcid":false,"given":"Giovanni","family":"Mori","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Infectious Diseases Unit, Ospedale Santa Chiara, 38122 Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Diotallevi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-6970","authenticated-orcid":false,"given":"Francesca","family":"Farina","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-6498","authenticated-orcid":false,"given":"Riccardo","family":"Lolatto","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Chiurlo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5826-9565","authenticated-orcid":false,"given":"Andrea","family":"Acerbis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Xue","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"},{"name":"Centre for Immuno-Oncology, National Cancer Institute, Eliminate NIH, Bethesda, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Clerici","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mastaglio","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Lupo Stanghellini","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ripa","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-8571","authenticated-orcid":false,"given":"Consuelo","family":"Corti","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Peccatori","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, 20161 Milan, Italy"},{"name":"Faculty of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-0851","authenticated-orcid":false,"given":"Massimo","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Oltolini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"},{"name":"Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, 20161 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2016.09.002","article-title":"Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations","volume":"31","author":"Pagano","year":"2017","journal-title":"Blood Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/myc.13130","article-title":"Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis","volume":"63","author":"Posteraro","year":"2020","journal-title":"Mycoses"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/myc.13205","article-title":"Epidemiology of invasive fungal disease in haematologic patients","volume":"64","author":"Souza","year":"2021","journal-title":"Mycoses"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bergamasco, M.D., Pereira, C.A.P., Arrais-Rodrigues, C., Ferreira, D.B., Baiocchi, O., Kerbauy, F., Nucci, M., and Colombo, A.L. (2021). Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach. J. Fungi, 7.","DOI":"10.3390\/jof7080588"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Puerta-Alcalde, P., and Garcia-Vidal, C. (2021). Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation. J. Fungi, 7.","DOI":"10.3390\/jof7100848"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11046-023-00754-w","article-title":"Epidemiology of invasive candidiasis in patients with hematologic malignancy on antifungal prophylaxis","volume":"188","author":"McCort","year":"2023","journal-title":"Mycopathologia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Int. Med. J."},{"key":"ref_11","unstructured":"(2023, October 10). Prevention and Treatment of Cancer-Related Infections, NCCN, Clinical Practice Guidelines in Oncology, Version 1.2023. Available online: https:\/\/www.nccn.org\/guidelines."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2014.02.018","article-title":"Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciac623","article-title":"Empiric vs. preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: A randomized trial of the European Organization for Research and Treatment of Cancer","volume":"76","author":"Maertens","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/cid\/ciad141","article-title":"Clinical impact of polymerase chain reaction\u2013based Aspergillus and azole resistance detection in invasive aspergillosis: A prospective multicenter study","volume":"77","author":"Huygens","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dannaoui, E. (2022). Recent developments in the diagnosis of mucormycosis. J. Fungi, 8.","DOI":"10.3390\/jof8050457"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/cid\/ciab1066","article-title":"Evaluation of serum Mucorales PCR for the diagnosis of Mucormycoses: The MODIMUCOR prospective trial","volume":"75","author":"Millon","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ghelfenstein-Ferreira, T., Verdurme, L., and Alanio, A. (2022). Analytical performance of the commercial MucorGenius assay as compared to an in-house qPCR assay to detect Mucorales DNA in serum specimens. J. Fungi, 8.","DOI":"10.3390\/jof8080786"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Aerts, R., Bevers, S., Beuselinck, K., Schauwvlieghe, A., Lagrou, K., and Maertens, J. (2022). Blood Mucorales PCR to track down Aspergillus and Mucorales co-infections in at-risk hematology patients: A case-control study. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.1080921"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jinf.2020.05.051","article-title":"Evaluation of MucorGenius\u00ae mucorales PCR assay for the diagnosis of pulmonary mucormycosis","volume":"81","author":"Guegana","year":"2020","journal-title":"J. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e3876","DOI":"10.1093\/cid\/ciaa1639","article-title":"Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through Next-Generation Sequencing of microbial cell-free DNA in plasma","volume":"73","author":"Hill","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Heldman, M.R., Ahmed, A.A., Liu, W., Vo, A., Keane-Candib, J., Stevens-Ayers, T., Boeckh, M., Blauwkamp, T.A., Fisher, C.E., and Hill, J.A. (2023). Serial quantitation of plasma microbial cell-free DNA before and after diagnosis of pulmonary invasive mold infections after hematopoietic cell transplant. J. Infect. Dis., jiad255.","DOI":"10.1093\/infdis\/jiad255"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(22)00166-1","article-title":"[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"9","author":"Douglas","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining Breakthrough Invasive Fungal Infection\u2013 Position Paper of the Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM)","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"ref_26","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06829.x","article-title":"Risk stratification for invasive aspergillosis in immunocompromised patients","volume":"1272","author":"Herbrecht","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/bmt.2017.222","article-title":"Foiling fungal disease post hematopoietic cell transplant: Review of prophylactic strategies","volume":"53","author":"Rubinstein","year":"2018","journal-title":"Bone Marrow Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/myc.13148","article-title":"Breakthrough invasive fungal infections: Who is at risk?","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"594.e7","DOI":"10.1016\/j.cmi.2015.02.019","article-title":"Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: A prospective observational study","volume":"21","author":"Hsu","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dkq121","article-title":"Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): A 6 year experience of the Cologne AML cohort","volume":"65","author":"Vehreschild","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1093\/jac\/dku227","article-title":"Systemic antifungal treatment after posaconazole prophylaxis: Results from the SEIFEM 2010-C survey","volume":"69","author":"Pagano","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","first-page":"681","article-title":"Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole","volume":"49","author":"Michallet","year":"2011","journal-title":"Med. Mycol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0507.2010.01979.x","article-title":"Posaconazole prophylaxis in patients with acute myelogenous leukaemia\u2014Results from an observational study","volume":"54","author":"Egerer","year":"2011","journal-title":"Mycoses"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1439-0507.2010.01980.x","article-title":"Clinical experience with posaconazole prophylaxis-a retrospective analysis in a haematological unit","volume":"54","author":"Hahn","year":"2011","journal-title":"Mycoses"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/514731","article-title":"Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)","volume":"28","author":"Viscoli","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/cid\/civ293","article-title":"Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)","volume":"61","author":"Cornely","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Friedman, D.Z.P., and Schwartz, I.S. (2019). Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens. J. Fungi, 5.","DOI":"10.3390\/jof5030067"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gangneux, J.P., Padoin, C., Michallet, M., Saillio, E., Kumichel, A., Peffault de La Tour, R., Ceballos, P., Gastinne, T., and Pigneux, A. (2020). Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study. J. Fungi, 6.","DOI":"10.3390\/jof6040281"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2040620720965846","DOI":"10.1177\/2040620720965846","article-title":"Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?","volume":"11","author":"Chen","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciac230","article-title":"Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients with Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies","volume":"75","author":"Rausch","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e25448","DOI":"10.1097\/MD.0000000000025448","article-title":"Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00520-020-05535-5","article-title":"Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections","volume":"29","author":"Hsu","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clml.2021.10.011","article-title":"Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study from the Acute Leukaemia French Association (ALFA) Group","volume":"22","author":"Michallet","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/myc.12924","article-title":"Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre","volume":"62","author":"Bowen","year":"2019","journal-title":"Mycoses"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","article-title":"Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies","volume":"50","author":"Hachem","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/1078155219876683","article-title":"Voriconazole prophylaxis in leukemic patients: A retrospective single-center study","volume":"26","author":"Bui","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Cattaneo, C., Marchesi, F., Terrenato, I., Bonuomo, V., Fracchiolla, N.S., Delia, M., Criscuolo, M., Candoni, A., Prezioso, L., and Facchinelli, D. (2022). High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. J. Fungi, 8.","DOI":"10.3390\/jof8060583"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.01527-13","article-title":"Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia","volume":"58","author":"Gomes","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","article-title":"Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study","volume":"77","author":"Epstein","year":"2018","journal-title":"J. Infect."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.diagmicrobio.2019.01.011","article-title":"Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: A prospective, observational study in France","volume":"94","author":"Ceballos","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: A SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000321504","article-title":"Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis","volume":"124","author":"Lewis","year":"2010","journal-title":"Acta Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wang, S.T., Chou, C.H., Chen, T.T., Lin, C.C., Bai, L.Y., Yeh, S.P., Ho, M.W., and Lien, M.Y. (2022). High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.1012334"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.clml.2020.08.013","article-title":"The Incidence of Invasive Fungal Infections in Patients with AML Treated with a Hypomethylating Agent","volume":"21","author":"Ozga","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jac\/dky550","article-title":"\u2018Real-life\u2019 analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study","volume":"74","author":"Dragonetti","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.01423-10","article-title":"Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: An economic modeling approach","volume":"55","author":"Cheng","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial","volume":"16","author":"Serve","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"ofac486","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of Invasive Fungal Infections in Patients with Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","article-title":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Verheggen","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bow, E.J., Vanness, D.J., Slavin, M., Cordonnier, C., Cornely, O.A., Marks, D.I., Pagliuca, A., Solano, C., Cragin, L., and Shaul, A.J. (2015). Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0855-6"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial","volume":"138","author":"Winston","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Harrison, N., Mitterbauer, M., Tobudic, S., Kalhs, P., Rabitsch, W., Greinix, H., Burgmann, H., Willinger, B., Presterl, E., and Forstner, C. (2015). Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: A retrospective cohort study. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1329-6"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"ofab596","DOI":"10.1093\/ofid\/ofab596","article-title":"Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?","volume":"9","author":"Roth","year":"2021","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med. Mycol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/mmy\/myaa106","article-title":"Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Kraljevic","year":"2021","journal-title":"Med. Mycol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT)","volume":"26","author":"Stern","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"874117","DOI":"10.3389\/fonc.2022.874117","article-title":"Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol)","volume":"12","author":"Malagola","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Busca, A., Cinatti, N., Gill, J., Passera, R., Dellacasa, C.M., Giaccone, L., Dogliotti, I., Manetta, S., Corcione, S., and De Rosa, F.G. (2022). Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience. Front. Cell Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.805514"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"511.e1","DOI":"10.1016\/j.jtct.2022.05.030","article-title":"Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center","volume":"28","author":"Lindsay","year":"2022","journal-title":"Transpl. Cell Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: A 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study","volume":"87","author":"Ramos","year":"2023","journal-title":"J. Infect."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"ofad424","DOI":"10.1093\/ofid\/ofad424","article-title":"Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results from a Subgroup Analysis of a Multicenter National Registry","volume":"10","author":"Pappas","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e14045","DOI":"10.1111\/tid.14045","article-title":"Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole","volume":"25","author":"Scott","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.blre.2023.101092","article-title":"Does PTCY increase the risk of infections?","volume":"62","author":"Mikulska","year":"2023","journal-title":"Blood Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"508.e1","DOI":"10.1016\/j.jtct.2022.04.023","article-title":"Invasive yeast infection after Haploidentical donor hematopoietic cell transplantation associated with cytokine release syndrome","volume":"28","author":"Little","year":"2022","journal-title":"Transpl. Cell Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41409-019-0475-7","article-title":"Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced intensity and myeloablative conditioning: A study on behalf of the francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)","volume":"54","author":"Fayard","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","article-title":"Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Esquirol","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e13611","DOI":"10.1111\/tid.13611","article-title":"Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China assessment of antifungal therapy in hematological diseases (CAESAR) study","volume":"23","author":"Sun","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/myc.13384","article-title":"Invasive aspergillosis in relapsed\/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey","volume":"65","author":"Dragonetti","year":"2022","journal-title":"Mycoses"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","article-title":"Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"93","author":"Mousset","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/myc.12213","article-title":"Our 2014 approach to breakthrough invasive fungal infections","volume":"57","author":"Maschmeyer","year":"2014","journal-title":"Mycoses"},{"key":"ref_107","first-page":"1621","article-title":"Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/mmy\/myy091","article-title":"Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management","volume":"57","author":"Girmenia","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/jac\/dkw199","article-title":"A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis","volume":"71","author":"Biehl","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_110","first-page":"237","article-title":"Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study","volume":"55","author":"Kim","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/AAC.01599-09","article-title":"Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling","volume":"54","author":"Snelders","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkx423","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: A post hoc analysis of the SECURE trial","volume":"73","author":"Kontoyiannis","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Chen, L., Wang, Y., Zhang, T., Li, Y., Meng, T., Liu, L., Hao, R., and Dong, Y. (2018). Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: A meta-analysis with trial sequential analysis. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3055-3"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/426815","article-title":"A European Organization for Research and Treatment of Cancer\u2013International Antimicrobial Therapy Group Study of Secondary Infections in Febrile, Neutropenic Patients with Cancer","volume":"40","author":"Akova","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/jac\/dkx444","article-title":"Changes in the epidemiological landscape of invasive candidiasis","volume":"73","author":"Lamoth","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciaa230","article-title":"Invasive aspergillosis due to Aspergillus section usti: A multicenter retrospective study","volume":"72","author":"Glampedakis","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41409-017-0039-7","article-title":"Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients","volume":"53","author":"Greco","year":"2018","journal-title":"Bone Marrow Transpl."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e00604-19","DOI":"10.1128\/JCM.00604-19","article-title":"A novel broad allele-specific TaqMan Real-Time PCR method to detect triazole-resistant strains of Aspergillus fumigatus, even with a very low percentage of triazole-resistant cells mixed with triazole-susceptible cells","volume":"57","author":"Wang","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/AAC.01287-13","article-title":"Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)","volume":"57","author":"Mellado","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e01374-20","DOI":"10.1128\/AAC.01374-20","article-title":"Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Cryptic Isolates from Aspergillus Section Fumigati","volume":"64","author":"Imbert","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Lamoth, F., Lewis, R.E., and Kontoyiannis, D.P. (2020). Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. J. Fungi, 7.","DOI":"10.3390\/jof7010017"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/cid\/ciaa1855","article-title":"Guidance on Imaging for Invasive Pulmonary Aspergillosis and Mucormycosis: From the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC\/MSGERC","volume":"72","author":"Alexander","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Thompson, G.R., Soriano, A., Honore, P.M., Bassetti, M., Cornely, O.A., Kollef, M., Kullberg, B.J., Pullman, J., Hites, M., and Fort\u00fan, J. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: Pooled data from two prospective randomised controlled trials. Lancet Infect. Dis., 2023.","DOI":"10.1016\/S1473-3099(23)00551-0"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: A clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin. Infect. Dis."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/1\/117\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:41:20Z","timestamp":1760103680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/1\/117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["microorganisms12010117"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms12010117","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]}}}